Ethosuximide

Routes
Oral (PO)
Half-Life (t½)
PO: 50h
Formula
C7H11NO2
Molecular Weight
141.17 g/mol
PubChem CID
3291
Aliases
Zarontin

Pharmacological Mechanism

T-type Ca²⁺ channel blocker in thalamocortical circuits — first-line for absence seizures (childhood). Doesn't treat tonic-clonic; specifically fits the spike-and-wave thalamic mechanism of absence epilepsy.

Half-Life & Elimination Curve (PO: 50h)

100%50%25%12.5%0%0h0×t½50h1×t½4.2d2×t½6.3d3×t½8.3d4×t½10.4d5×t½0×t½ (0h): 100% remaining (~9.74 mg/L)1×t½ (50h): 50% remaining (~4.87 mg/L)2×t½ (4.2d): 25% remaining (~2.44 mg/L)3×t½ (6.3d): 12.5% remaining (~1.22 mg/L)4×t½ (8.3d): 6.3% remaining (~0.609 mg/L)5×t½ (10.4d): 3.1% remaining (~0.304 mg/L)
Plasma (PO)t½ Decay (50h)
  • 0×t½0h100% (9.74 mg/L)
  • 1×t½50h50% (4.87 mg/L)
  • 2×t½4.2d25% (2.44 mg/L)
  • 3×t½6.3d12.5% (1.22 mg/L)
  • 4×t½8.3d6.3% (0.609 mg/L)
  • 5×t½10.4d3.1% (0.304 mg/L)
Elimination t½50h (PO)
Rate Constant (ke)0.0139 h⁻¹
Time to Peak (Tmax)3.33h
Est. Peak (Cmax)9.74 mg/L
Clearance (CL)0.679 L/h
97% Washout (5×t½)10.4d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References